Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says
Researchers believe that Terry Horgan, a 27-year-old man with Duchenne muscular dystrophy who was the first person to receive a designer CRISPR therapy, died from an immune reaction likely related to the high dose of viral vector used to deliver the therapy.
A preprint paper published Wednesday described findings from Terry’s autopsy, following months of uncertainty around what exactly led to his death in October just eight days after he received the treatment. The researchers concluded that Terry’s death was not likely related to gene editing, since there was only a small signal of the CRISPR expression in the liver, and none in other organs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters